Biological Information

Background Information:

The PathHunter® Adalimumab Bioassay Kit provides an easy-to-use cell based assay to measure drug potency and detect neutralizing antibodies. This bioassay is designed to measure IkB degradation as a result of TNF alpha-mediated activation of the NF-kB signaling pathway. The included cells overexpress IκB tagged with PL. Addition of the detection reagent containing EA, forces complementation of the two enzyme fragments. The resulting active enzyme hydrolyzes the substrate to generate a chemiluminescent signal which is proportional to the degree of IκB stabilization. This assay has been optimized and qualified with Humira (not supplied in the bioassay kit). Humira is a registered trademark of AbbVie, Inc. The bioassay kit contains all the materials needed to run the assay, including cryopreserved cells, cell plating reagent, control agonist, detection reagents, and assay plates.

Please reach out to Tech Support at DiscoverXSupportUS@discovery.eurofinsus.com for lot specific CoA.

Target Class:

Signaling Pathway

Family:

Tumour Necrosis Factor (TNF)

Protein Name:

IKBA

Protein Aliases:

IkB-alpha|IkappaBalpha|Major histocompatibility complex enhancer-binding protein MAD3

Accession Number:

NM_020529

UniProt Number:

P25963

Gene Name:

NFKBIA

Gene ID:

4792

Gene Aliases:

IKBA|MAD3|NFKBI

Target Species:

Human

Cell Background:

A549

Usage

Product Type:

Bioassay Kits

Application:

Potency, Commercial Release & Stability

Kit Components:

KitComponent

Storage Conditions:

Store in vapor phase of liquid nitrogen.

Usage disclaimer:

These products may be covered by issued US and/or foreign patents, patent applications and subject to a Limited Use Label License. Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information.

Assay Information

Assay Type:

Cell Based, Qualified

Assay Measures:

SH2 Recruitment

Detection Method:

Chemiluminescence

Bioassay Data

INN Drug Name:

Adalimumab

Qualified With:

Humira®

Trademark Statement:

Humira® is a registered trademark of AbbVie, Inc.

Clinical Relevance

Therapeutic Area:

Inflammation/Allergy

Additional Information

Brand:

PathHunter®